Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06495164 · ClinicalTrials.gov registry record
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
A clinical trial of Breast Cancer and Malignant Neoplasm of Breast, sponsored by Pfizer.
- Active
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT06495164 is a study of Breast Cancer and Malignant Neoplasm of Breast that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 1 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06495164, a study of Breast Cancer and Malignant Neoplasm of Breast, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
Palbociclib, the first oral CDK4/6 inhibitor, is an approved medicine indicated for the treatment of a kind of advanced/metastatic breast cancer (MBC), called hormone receptors positive (HR+)/ Human epidermal growth factor receptor 2 negative (HER2-) disease. Palbociclib is given orally in combination with hormonal therapies. The purpose of this study is to better understand how Palbociclib combination is used in real-life conditions and its clinical impact compared with hormonal therapy. The study will also evaluate how long patients take the different CDK 4/6 inhibitor drugs and whether using those drugs impacts the use of chemotherapy later. Male and female patients aged 18 years old or more presenting the following conditions will be selected for the study: * HR+/HER2- MBC * First treatment with Palbociclib, hormonal therapy, or other CDK4/6 inhibitors after MBC diagnosis The study will use data without personal identity, which were obtained from medical records in routine clinical practice.
Conditions Studied
Interventions
- DRUG Palbociclib
- DRUG Abemaciclib
- DRUG Ribociclib
- DRUG Aromatase inhibitor
Study Locations (1)
New York
- Pfizer New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2026-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06495164
The ClinicalTrials.gov registry entry for NCT06495164 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Palbociclib is the first listed.
NCT06495164 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06495164 about?
NCT06495164 is a clinical study titled "A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer". Palbociclib, the first oral CDK4/6 inhibitor, is an approved medicine indicated for the treatment of a kind of advanced/metastatic breast cancer (MBC), called hormone receptors positive (HR+)/ Human epidermal growth factor receptor 2 negative (HER2-) disease. Palbociclib is given orally in combinati...
What is the current status of trial NCT06495164?
This trial is currently active not recruiting. The enrollment target is 1 participants. The study started on 2024-06-24. Estimated completion is 2026-12-30.
What conditions does trial NCT06495164 study?
This clinical trial studies the following conditions: Breast Cancer, Malignant Neoplasm of Breast.
What interventions are being tested in trial NCT06495164?
The interventions under investigation include: Palbociclib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG), Aromatase inhibitor (DRUG).
Who is sponsoring clinical trial NCT06495164?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06495164 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.